Page last updated: 2024-08-26

lysophosphatidic acid and geranylgeranylacetone

lysophosphatidic acid has been researched along with geranylgeranylacetone in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hashimoto, K; Morishige, K; Murata, Y; Sakata, M; Sawada, K; Shimizu, S; Tahara, M; Tasaka, K	1
Hashimoto, K; Kimura, T; Morishige, K; Ogata, S; Sakata, M; Sawada, K; Shimizu, S; Tahara, M; Tasaka, K	1
Fishman, DA; Wang, F	1

Reviews

1 review(s) available for lysophosphatidic acid and geranylgeranylacetone

Article	Year
Lysophosphatidic acid and invasion. Cancer treatment and research, 2009, Volume: 149 Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cyclooxygenase 2; Diterpenes; Female; Humans; Interleukins; Intracellular Signaling Peptides and Proteins; Lysophospholipids; Membrane Lipids; Mice; Multienzyme Complexes; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Ovarian Neoplasms; Peptide Hydrolases; Phosphodiesterase I; Phospholipases A; Phosphoric Diester Hydrolases; Pyrophosphatases; Receptors, Lysophosphatidic Acid; Signal Transduction; Sphingosine; Vascular Endothelial Growth Factor A	2009

Article

Year

Lysophosphatidic acid and invasion.

Cancer treatment and research, 2009, Volume: 149

Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cyclooxygenase 2; Diterpenes; Female; Humans; Interleukins; Intracellular Signaling Peptides and Proteins; Lysophospholipids; Membrane Lipids; Mice; Multienzyme Complexes; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Ovarian Neoplasms; Peptide Hydrolases; Phosphodiesterase I; Phospholipases A; Phosphoric Diester Hydrolases; Pyrophosphatases; Receptors, Lysophosphatidic Acid; Signal Transduction; Sphingosine; Vascular Endothelial Growth Factor A

2009

Other Studies

2 other study(ies) available for lysophosphatidic acid and geranylgeranylacetone

Article	Year
Geranylgeranylacetone inhibits lysophosphatidic acid-induced invasion of human ovarian carcinoma cells in vitro. Cancer, 2005, Apr-01, Volume: 103, Issue:7 Topics: Actins; Acute-Phase Proteins; Cell Shape; Cell Survival; Cytoskeletal Proteins; Diterpenes; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Lysophospholipids; Neoplasm Invasiveness; Ovarian Neoplasms; Paxillin; Phosphoproteins; Phosphorylation; Tumor Cells, Cultured	2005
Geranylgeranylacetone inhibits ovarian cancer progression in vitro and in vivo. Biochemical and biophysical research communications, 2007, Apr-27, Volume: 356, Issue:1 Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Disease Progression; Diterpenes; Dose-Response Relationship, Drug; Female; Humans; Lysophospholipids; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Phosphorylation; ras Proteins; Time Factors; Xenograft Model Antitumor Assays	2007

Article

Year

Geranylgeranylacetone inhibits lysophosphatidic acid-induced invasion of human ovarian carcinoma cells in vitro.

Cancer, 2005, Apr-01, Volume: 103, Issue:7

Topics: Actins; Acute-Phase Proteins; Cell Shape; Cell Survival; Cytoskeletal Proteins; Diterpenes; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Lysophospholipids; Neoplasm Invasiveness; Ovarian Neoplasms; Paxillin; Phosphoproteins; Phosphorylation; Tumor Cells, Cultured

2005

Geranylgeranylacetone inhibits ovarian cancer progression in vitro and in vivo.

Biochemical and biophysical research communications, 2007, Apr-27, Volume: 356, Issue:1

Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Disease Progression; Diterpenes; Dose-Response Relationship, Drug; Female; Humans; Lysophospholipids; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Phosphorylation; ras Proteins; Time Factors; Xenograft Model Antitumor Assays

2007